Download PDF
Kardiologie up2date 2016; 12(01): 21-23
DOI: 10.1055/s-0041-108112
Hotline – Thrombozyten und Gerinnungssystem bei kardiovaskulären Erkrankungen
© Georg Thieme Verlag KG Stuttgart · New York

Direkte orale Antikoagulanzien – wichtige Unterschiede und Kerndaten

M. Hubald
,
C. Mues
,
R. H. Strasser
Further Information

Publication History

Publication Date:
08 March 2016 (online)

Also available at
    Permissions and Reprints All articles of this category

Corrected by:

Direkte orale Antikoagulanzien – wichtige Unterschiede und KerndatenKardiologie up2date 2016; 12(02): 130-130
DOI: 10.1055/s-0042-108841

Abstract

Direct oral anticoagulants (DOAC) are alternatives to vitamin K antagonists for prophylaxis of stroke in non-valvular atrial fibrillation and prophylaxis and therapy of venous thromboembolism. Currently there is a choice between the four DOACs Apixaban, Dabigatran, Edoxaban and Rivaroxaban. Strategies for differential therapy regarding indications, dosing, costs, drug interactions and cautions concerning impaired renal function are discussed briefly.

 

  • Literatur

  • 1 EINSTEIN Investigators. Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510
    CrossrefPubMedGoogle Scholar
  • 2 EINSTEIN–PE Investigators. Büller HR, Prins MH, Lensin AW et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297
    CrossrefPubMedGoogle Scholar
  • 3 AMPLIFY Investigators. Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808
    CrossrefPubMedGoogle Scholar
  • 4 RE-COVER Study Group. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352
    CrossrefPubMedGoogle Scholar
  • 5 RE-COVER II Trial Investigators. Schulman S, Kakkar AK, Goldhaber SZ et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129: 764-772
    CrossrefPubMedGoogle Scholar
  • 6 Hokusai-VTE Investigators. Büller HR, Décousus H, Grosso MA et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415
    CrossrefPubMedGoogle Scholar
  • 7 ROCKET AF Investigators. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891
    CrossrefPubMedGoogle Scholar
  • 8 ARISTOTLE Committees and Investigators. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992
    CrossrefPubMedGoogle Scholar
  • 9 RE-LY Steering Committee and Investigators. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
    CrossrefPubMedGoogle Scholar
  • 10 ENGAGE AF-TIMI 48 Investigators. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104
    CrossrefPubMedGoogle Scholar
  • 11 Pollack CV Jr, Reilly PA, Eikelboom J et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373: 511-520
    CrossrefPubMedGoogle Scholar